European Commission Approves Purchase Agreement Amendment for Valneva's Inactivated COVID-19 VaccineGlobeNewsWire • 07/20/22
Clover's COVID-19 Vaccine Candidate Demonstrates Strong Cross-Neutralization Against Omicron as a Homologous BoosterGlobeNewsWire • 06/27/22
Valneva Receives Marketing Authorization in Europe for Inactivated Whole-Virus COVID-19 Vaccine VLA2001GlobeNewsWire • 06/24/22
Valneva Receives Positive CHMP Opinion for Marketing Authorization of its Inactivated COVID-19 Vaccine Candidate in EuropeGlobeNewsWire • 06/23/22
Clover Doses First Participants in Phase 3 Trial Evaluating SCB-2019 as a Heterologous COVID-19 Booster Following Prior Vaccination with Inactivated, mRNA or Viral Vector VaccinesGlobeNewsWire • 06/14/22
Valneva Provides Update on European Inactivated, Whole-Virus COVID-19 Vaccine Program VLA2001GlobeNewsWire • 06/10/22
Valneva Receives Notice of European Commission's Intent to Terminate COVID-19 Vaccine Purchase AgreementGlobeNewsWire • 05/16/22
Dynavax Technologies Corp (DVAX) CEO Ryan Spencer on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/06/22
Dynavax Technologies (DVAX) Misses Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/05/22
Clover's Bivalent COVID-19 Vaccine Candidate Demonstrates Broad Neutralization Against Omicron and Other Variants of ConcernGlobeNewsWire • 05/05/22
Valneva Initiates Heterologous Booster Trial of Inactivated, COVID-19 Vaccine CandidateGlobeNewsWire • 05/04/22
Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022PRNewsWire • 04/21/22
Clover's Efficacy Data in Previously-Infected Individuals is Published in Lancet Infectious DiseaseGlobeNewsWire • 04/20/22
Clover Presents Updated Durability and Booster Data for COVID-19 Vaccine Candidate at World Vaccine Congress Washington 2022GlobeNewsWire • 04/19/22